Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079549 | 0.85 | SMN1; SMN2 (0.56) | HPGDALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL11680022 | 0.83 | HPGD (0.73) | HPGDALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL3435778 | 0.82 | SMN1; SMN2 (0.60) | HPGDALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL12011604 | 0.82 | HPGD (0.58) | HPGDALDH1A1SMN1; SMN2TP53HTT | |
| SCHEMBL10029339 | 0.82 | KDM4E (0.51) | HPGDALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL7265678 | 0.82 | HPGD (0.51) | HPGDALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL3033838 | 0.82 | TP53 (0.67) | HPGDALDH1A1SMN1; SMN2TP53POLB | |
| SCHEMBL3111273 | 0.81 | KDM4E (0.54) | HPGDALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL3435195 | 0.81 | LMNA (0.52) | HPGDALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL5925601 | 0.81 | L3MBTL1 (0.56) | HPGDALDH1A1LMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8481581-B2 | S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2609917-A1 | Triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2433633-A1 | Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2402011-A1 | Intermediates in the synthesis of S-triazolyl alpha-mercaptoacetanildes as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2135608-B1 | S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES INC (US) | 2011-10-12 | — | — | EP | disclosed |
| US-8003681-B2 | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester | ARDEA BIOSCIENCES, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003681-B2 | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester | ARDEA BIOSCIENCES, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110190491-A1 | S-TRIAZOLE ALPHA- MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7947721-B2 | able to inhibit various mutated RTs, including K103N, Y181C and Y188L | Ardes Biosciences Inc. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947721-B2 | able to inhibit various mutated RTs, including K103N, Y181C and Y188L | Ardes Biosciences Inc. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100267724-A2 | S-TRIAZOLE ALPHA-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100081827-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081827-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | HPGD 1365/4885ALDH1A1 1407/4885LMNA 4749/4885 |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | GRHPR, POLR2H, ME2 | HPGD 2822/4885ALDH1A1 1839/4885LMNA 4176/4885 |
| US-20110190491-A1 | S-TRIAZOLE ALPHA- MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, QTRT1 | HPGD 1202/4885ALDH1A1 1135/4885LMNA 4693/4885 |
| US-20100267724-A2 | S-TRIAZOLE ALPHA-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, QTRT1 | HPGD 1202/4885ALDH1A1 1135/4885LMNA 4693/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | HPGD 1370/4885ALDH1A1 1574/4885LMNA 4686/4885 |
| US-20100081827-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | GRHPR, POLR2H, DECR1 | HPGD 2771/4885ALDH1A1 1632/4885LMNA 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.